Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Intravenous immunoglobulin (IVIg) is a potential alternative treatment for anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) with less toxicity than conventional immunosuppressive agents. This randomized, placebo-controlled trial aimed to investigate the efficacy of a s...

Bibliografski detalji
Glavni autori:	Jayne, DR, Chapel, H, Adu, D, Misbah, S, O'Donoghue, D, Scott, D, Lockwood, C
Format:	Journal article
Jezik:	English
Izdano:	2000

Slični predmeti

Placebo-controlled trial of intravenous immunoglobulin in ANCA-associated systemic vasculitis.
od: Jayne, D, i dr.
Izdano: (1999)

Cardiovascular outcomes in ANCA associated vasculitis
od: Mukhtyar, C, i dr.
Izdano: (2008)

Diagnosis and management of ANCA associated vasculitis.
od: Berden, A, i dr.
Izdano: (2012)

Comparison of disease activity measures for ANCA-associated vasculitis.
od: Merkel, P, i dr.
Izdano: (2004)

Explaining fatigue in ANCA-associated vasculitis.
od: Basu, N, i dr.
Izdano: (2013)

Explaining fatigue in ANCA-associated vasculitis
od: Basu, N, i dr.
Izdano: (2013)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
od: Arnold, D, i dr.
Izdano: (2010)

ANCA Associated Vasculitis Subtypes: Response [Letter]
od: Merkel PA, i dr.
Izdano: (2022-09-01)

Markers for work disability in ANCA-associated vasculitis
od: Basu, N, i dr.
Izdano: (2013)

Predictors of renal involvement in ANCA associated vasculitis
od: Kronbichler, A, i dr.
Izdano: (2018)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
od: Lapraik, C, i dr.
Izdano: (2007)

Long-term survival of ANCA-associated vasculitis
od: Flossmann, O, i dr.
Izdano: (2009)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
od: Suppiah, R, i dr.
Izdano: (2011)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
od: Salisbury, E, i dr.
Izdano: (2003)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
od: Basu, N, i dr.
Izdano: (2014)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
od: Jones, R, i dr.
Izdano: (2010)

Intravenous immunoglobulin therapy.
od: Chapel, H
Izdano: (1996)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
od: Basu, N, i dr.
Izdano: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis
od: Basu, N, i dr.
Izdano: (2014)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
od: Yew, S, i dr.
Izdano: (2012)

Thyroid disease in ANCA-associated vasculitis: a clinical and epidemiological study
od: David Jayne, i dr.
Izdano: (2024-07-01)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
od: Ntatsaki, E, i dr.
Izdano: (2014)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
od: Luqmani, R, i dr.
Izdano: (2007)

26 Lessons learned from complement inhibition in ANCA vasculitis
od: David Jayne
Izdano: (2021-04-01)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
od: Salisbury, E, i dr.
Izdano: (2004)

Long-term patient survival in ANCA-associated vasculitis
od: Flossmann, O, i dr.
Izdano: (2011)

Long-term patient survival in ANCA-associated vasculitis.
od: Flossmann, O, i dr.
Izdano: (2011)

Interstitial Lung Disease with ANCA-associated Vasculitis
od: Yasuhiro Katsumata, i dr.
Izdano: (2015-01-01)

Updates in ANCA-associated vasculitis
od: Carolyn Ross, i dr.
Izdano: (2022-07-01)

Epidemiology of ANCA associated vasculitis
od: Wenche Koldingsnes, i dr.
Izdano: (2008-01-01)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
od: Suppiah, R, i dr.
Izdano: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
od: Suppiah, R, i dr.
Izdano: (2011)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
od: Yew, S, i dr.
Izdano: (2012)

Long-term patient survival in ANCA-associated vasculitis.
od: Flossmann, O, i dr.
Izdano: (2011)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
od: Merkel, P, i dr.
Izdano: (2009)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
od: Basu, N, i dr.
Izdano: (2012)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
od: Zachary S. Wallace, i dr.
Izdano: (2019-12-01)

Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity.
od: Olivier M Lardinois, i dr.
Izdano: (2019-01-01)

Home intravenous immunoglobulin therapy.
od: Chapel, H, i dr.
Izdano: (1988)

Damage assessment in ANCA-associated vasculitis.
od: Bhamra, K, i dr.
Izdano: (2012)